Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 17

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 17
---
vested options to purchase shares of common stock held by     
 Mr. Hawkins that will vest within 60 days of April 10, 2025. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants  
 that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr. Hawkins is the Chairman of the Board of Plus Therapeutics and his address is c/o Plus 
 Therapeutics, Inc., 2710 Reed Road, Suite 160, Houston, Texas 77051.                                                                                                                                                                                |

| (12) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                    
 securities purchased by Mr. Howard Clowes in the May 2024 PIPE Financing: (i) 9,804 shares of common stock; (ii) 9,804 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 9,804 shares of             
 common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 16,693 shares of common stock held by Mr. Clowes and 15,502 shares of common stock underlying unvested options to purchase shares of common stock held by   
 Mr. Clowes that will vest within 60 days of April 10, 2025. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants 
 that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr. Clowes is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, 
 Inc., 2710 Reed Road, Suite 160, Houston, Texas 77051.                                                                                                                                                                                            |

| (13) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                       
 securities purchased by Mr. Robert Lenk, Ph.D. in the May 2024 PIPE Financing: (i) 4,167 shares of common stock; (ii) 4,167 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,167 shares of           
 common stock issuable upon the exercise of